Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Shortened dual antiplatelet therapy and low-dose ticagrelor after PCI in ACS
ChiCTR1900023825Phase 4Not yet recruiting
- Sponsor
- Tianjin Union Medical Center
- Start
- Jul 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of ticagrelor and aspirin in acute coronary syndrome (ACS) (3 arms), sponsored by Tianjin Union Medical Center. Primary endpoints: Platelet aggregation rate and Urinary 11-dehydrothromboxane B2 content. Planned start Jul 2019; status: not yet recruiting.
02
Drugs
ticagreloraspirin
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on ChiCTR1900023825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900023825.